J W Ho, D E Moody
Index: Anal. Biochem. 203 , 348, (1992)
Full Text: HTML
Debrisoquine and sparteine are prototype substrates of a genetic deficiency in cytochrome P450-dependent drug metabolism. Sensitive assays of in vitro oxidation of sparteine and debrisoquine are required for evaluation of this polymorphism. The activities were measured by quantitative analysis of 2-dehydrosparteine and 4-hydroxydebrisoquine production, respectively, using capillary column gas chromatography coupled with mass selective ion detection. With a single extraction, separation of parent drug, metabolite, and a suitable internal standard was readily achievable. Time-dependent production of both metabolites could be detected from as little as 40 micrograms of microsomal protein. Both activities showed a maximal activity with a 240-min incubation period. The ability to simultaneously quantify the parent drug and its metabolite suggests it would also be useful for evaluation of in vivo metabolism.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
DEBRISOQUIN SULFATE
CAS:581-88-4 |
C10H13N3.1/2H2O4S |
Distinct serum metabolomics profiles associated with maligna...
2015-01-01 [BMC Genomics 16 Suppl 1 , S1, (2015)] |
A Comprehensive Metabolomic Investigation in Urine of Mice E...
2015-06-01 [Radiat. Res. 183 , 665-74, (2015)] |
Global Metabolomic Identification of Long-Term Dose-Dependen...
2015-08-01 [Radiat. Res. 184 , 121-33, (2015)] |
Development of a metabolomic radiation signature in urine fr...
2014-04-01 [Radiat. Res. 181(4) , 350-61, (2014)] |
Inactivation of Human Cytochrome P450 3A4 and 3A5 by Droneda...
2016-01-01 [Mol. Pharmacol. 89 , 1-13, (2015)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved